LCA-0062
Asset
Bispecific antibody cataLYTAC degrader designed to degrade multiple IgE molecules per degrader.
- Stage
- Preclinical
- Modality
- Antibody
- Target
- Not known
- 6
- Indications
- 0
- Trials
- 1
- Developer
Indications
6Allergic asthma
Preclinical, lyciatx.com, 10 Oct 2026
Allergic rhinitis
Preclinical, lyciatx.com, 10 Oct 2026
Chronic rhinosinusitis with nasal polyps
Preclinical, lyciatx.com, 10 Oct 2026
3 more
In the full profile
- Owner and partners1
- Competitors1
Every asset’s record: target, stage, trials and the evidence behind it.